Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.

Authors

Rishi R Lulla
Stewart Goldman
Tohru Yamada
Craig W Beattie
Linda Bressler
Michael Pacini
Ian F Pollack
Paul Graham Fisher
Roger J. Packer, George Washington UniversityFollow
Ira J Dunkel
Girish Dhall
Shengjie Wu
Arzu Onar
James M Boyett
Maryam Fouladi

Document Type

Journal Article

Publication Date

9-1-2016

Journal

Neuro-oncology

Volume

18

Issue

9

Inclusive Pages

1319-1325

DOI

10.1093/neuonc/now047

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Lulla, R., Goldman, S., Yamada, T., Beattie, C., Bressler, L., Pacini, M., Pollack, I., Fisher, P., Packer, R. J., Dunkel, I., Dhall, G., Wu, S., Onar, A., Boyett, J., & Fouladi, M. (2016). Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.. Neuro-oncology, 18 (9). http://dx.doi.org/10.1093/neuonc/now047

Peer Reviewed

1

Open Access

1